TWI797366B - 吡咯并[1,2-b]嗒衍生物 - Google Patents

吡咯并[1,2-b]嗒衍生物 Download PDF

Info

Publication number
TWI797366B
TWI797366B TW108128802A TW108128802A TWI797366B TW I797366 B TWI797366 B TW I797366B TW 108128802 A TW108128802 A TW 108128802A TW 108128802 A TW108128802 A TW 108128802A TW I797366 B TWI797366 B TW I797366B
Authority
TW
Taiwan
Prior art keywords
alkyl
cycloalkyl
nhc
aryl
heterocyclyl
Prior art date
Application number
TW108128802A
Other languages
English (en)
Chinese (zh)
Other versions
TW202021966A (zh
Inventor
史蒂芬 安曼
伊麗莎白 Ｍ 貝肯
格迪米納斯 布立基茲
阿爾伯特 陳
建宏 周
傑若米 Ｊ 科特爾
瑪麗蓮 恩杜克
詹姆士 Ｇ 泰勒
納森 Ｅ 萊特
征宇 楊
西拉 Ｍ 力普菲爾
Original Assignee
美商基利科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商基利科學股份有限公司 filed Critical 美商基利科學股份有限公司
Publication of TW202021966A publication Critical patent/TW202021966A/zh
Application granted granted Critical
Publication of TWI797366B publication Critical patent/TWI797366B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
TW108128802A 2018-08-13 2019-08-13 吡咯并[1,2-b]嗒衍生物 TWI797366B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862718273P 2018-08-13 2018-08-13
US62/718,273 2018-08-13

Publications (2)

Publication Number Publication Date
TW202021966A TW202021966A (zh) 2020-06-16
TWI797366B true TWI797366B (zh) 2023-04-01

Family

ID=67777432

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108128802A TWI797366B (zh) 2018-08-13 2019-08-13 吡咯并[1,2-b]嗒衍生物

Country Status (9)

Country Link
US (1) US11572362B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837012A1 (cg-RX-API-DMAC7.html)
JP (2) JP7169429B2 (cg-RX-API-DMAC7.html)
KR (1) KR102660255B1 (cg-RX-API-DMAC7.html)
CN (1) CN112566697B (cg-RX-API-DMAC7.html)
AU (2) AU2019321424B2 (cg-RX-API-DMAC7.html)
CA (1) CA3105795C (cg-RX-API-DMAC7.html)
TW (1) TWI797366B (cg-RX-API-DMAC7.html)
WO (1) WO2020036979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210036A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
US9624246B2 (en) 2015-02-06 2017-04-18 Merck Patent Gmbh Pyridazinone macrocycles as IRAK inhibitors and uses thereof
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
TW202340194A (zh) * 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210036A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds

Also Published As

Publication number Publication date
CA3105795A1 (en) 2020-02-20
CA3105795C (en) 2024-01-16
EP3837012A1 (en) 2021-06-23
US20200071333A1 (en) 2020-03-05
AU2019321424B2 (en) 2022-07-14
JP7169429B2 (ja) 2022-11-10
AU2022204399A1 (en) 2022-07-14
WO2020036979A1 (en) 2020-02-20
KR20210044819A (ko) 2021-04-23
TW202021966A (zh) 2020-06-16
CN112566697B (zh) 2024-04-16
CN112566697A (zh) 2021-03-26
JP2022130716A (ja) 2022-09-06
JP2021535904A (ja) 2021-12-23
KR102660255B1 (ko) 2024-04-25
AU2019321424A1 (en) 2021-01-28
US11572362B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
TWI733982B (zh) 吡咯并[1,2-b]嗒衍生物
US11535622B2 (en) Pyrrolo[1,2-b] pyridazine derivatives
TWI727392B (zh) 噻二唑irak4抑制劑
TWI797366B (zh) 吡咯并[1,2-b]嗒衍生物
JP2023002695A (ja) ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体
HK40045601A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40045601B (zh) 作为irak4抑制剂的吡咯并[1，2-b]哒嗪衍生物
HK40045605A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors